Anti-TREM1 antibodies and methods of use thereof

US12110327B2 · kind B2 · utility

Assignee

• Alector LLC

Inventors

• Andrew Pincetic · New York, US
• Arnon Rosenthal · Woodside, US
• Helen LAM · Union City, US
• Francesca Avogadri-Connors · Lasów Chojnowskich, US
• Seung-Joo Lee · Goyang-si, KR

Key dates

• Filing date: Sep 13, 2022
• Grant date: Oct 8, 2024
• Expiry date: Sep 13, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.